Neoantigens in cancer immunotherapy
Citations Over TimeTop 1% of 2015 papers
Abstract
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Related Papers
- → B7-H3/CD276: An Emerging Cancer Immunotherapy(2021)282 cited
- → pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review(2020)95 cited
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → Triggering Immune System With Nanomaterials for Cancer Immunotherapy(2022)23 cited
- → Nanotechnology-Based Bacterial Immunotherapy(2022)1 cited